Implantica Reports Q1 2025 Results: Revenue Up, FDA Application Progresses
Implantica's Q1 2025 report shows a 25% increase in net sales and positive feedback from the U.S. FDA on its RefluxStop™ premarket approval application.
Implantica has released its interim report for the first quarter of 2025, announcing a 25% increase in net sales to EUR 745,000 (from EUR 596,000 in Q1 2024) and significant progress in its regulatory pathway in the United States. The company reported a notable decrease in operating loss to EUR 4.17 million.
A key development for the quarter was the positive feedback received from the U.S. Food and Drug Administration (FDA) regarding Implantica's Premarket Approval (PMA) application for its RefluxStop™ device. The FDA has accepted Module 1, which details the quality systems and manufacturing information, marking this module as closed and advancing the review process. Concurrently, a large-scale, real-world study in Germany involving 79 patients demonstrated a 100% median improvement in quality of life as measured by the GERD-HRQL questionnaire.
In Europe, RefluxStop™ is CE-marked and available in several countries, including Germany, the UK, Switzerland, Spain, Italy, France, Austria, Sweden, and Norway. Spain has seen continued adoption, with 15 centers of excellence offering the procedure within two years of its launch. The company also initiated a randomized clinical trial to compare RefluxStop™ against the traditional Nissen fundoplication procedure.
Financially, Implantica reported an adjusted gross margin of 97% and a reduced loss after tax. Cash and short-term investments stood at EUR 60.3 million at the end of the period, providing a solid financial footing for ongoing operations and expansion efforts. The company also highlighted the expansion of its surgical centers in Spain and educational meetings for gastrointestinal experts.